CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer

Clinical Outcome of CT-guided Radioactive Iodine-125 Seeds Implantation for Inoperable Early Stage Non-small Cell Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03916367

Enrollment

Registered

2019-04-16

Start date

2010-12-15

Completion date

2019-02-15

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Stage Non-small Cell Lung Cancer

Keywords

radioactive iodine-125 seeds implantation, non-small cell lung cancer, early stage

Brief summary

This study observes the efficacy and side effects of CT-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.

Detailed description

Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study collects the data of patients with early stage (stage I-II, N0) non-small cell lung cancer who underwent CT-guided radioactive Iodine-125 seed implantation from 2010 to 2018. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse effects were observed. Local control(LC) time and overall survival(OS) time are evaluated.

Interventions

RADIATIONCT-guided Radioactive I-125 Seeds Implantation

The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* histological proven non-small cell lung cancer * UICC (Union for International Cancer Control) stage was T1-3N0M0 (stage Ia-IIb) * inoperable and CT-guided radioactive iodine-125 seeds brachytherapy was used as the initial treatment without external beam radiotherapy

Exclusion criteria

* actual dose of covers 90% target volume (D90) less than 100 Gy in postoperative validation * case information and/or follow-up information was unavailable

Design outcomes

Primary

Measure	Time frame	Description
Local control time	Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.	The time from the date of seeds implantation to the date of recurrence of the implanted tumor or the date of last observation.
Overall survival time	Outcomes were followed up every 3 months after enrollment. The last follow-up timepoint is February 2019.	The time from the date of seeds implantation to the date of death from any cause or the date of last observation.

Secondary

Measure	Time frame	Description
Incidence of adverse events	Outcomes were followed up every 3 months after seeds implantation. The last follow-up timepoint is February 2019.	The adverse events were evaluated by the common terminology criteria for adverse events (CTCAE). The rate of each adverse event was measured.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026